ENSC
Bullish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Ensysce Biosciences, Inc.
- Nom
- Ensysce Biosciences, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $9.7M
- Employés
- 9
- PDG
- D. Lynn Kirkpatrick
- Site web
- https://www.ensysce.com
- Marché
- AIMCANFKALAKZIAOGENQLGN
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 908614 titres (~444169 USD)
- Insiders
- GOWER BOB G
- Total bought
-
$444,169
Avg buy (VWAP, 90d window) $0.49 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-07
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-07 | GOWER BOB G | Buy · P | 400,000 | $0.49 | $198,000 | Form 4 |
| 2026-04-23 | GOWER BOB G | Buy · P | 508,614 | $0.48 | $246,169 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bullish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
ENSC presents a compelling event-driven setup with a high-conviction M&A catalyst (Cy Biopharma acquisition, FDA Orphan Drug status, insider cluster buying), but the underlying financials are critically impaired with…
The first sentence of the analysis written for ENSC on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.59 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 1.586 | 2.421 | 0.687 | 0.560 | 0.950 | |
| Quick Ratio | 1.586 | 2.421 | 0.687 | 0.560 | 0.977 | |
| Solvency Ratio | -2.226 | -3.602 | -3.159 | -2.438 | -1.183 | |
| Cash Ratio | 0.944 | 1.587 | 0.337 | 0.333 | 0.744 | |
| Price To Earnings Ratio | -0.231 | -1.781 | -3.390 | -0.968 | -47.571 | |
| Price To Earnings Growth Ratio | 0.018 | 0.696 | 0.035 | 0.016 | 0.001 | |
| Forward Price To Earnings Growth Ratio | 0.018 | 0.696 | 0.035 | 0.016 | 0.001 | |
| Price To Earnings Diluted Ratio | -0.231 | -1.781 | -3.390 | -0.968 | -47.571 | |
| Price To Earnings Diluted Growth Ratio | 0.018 | 0.696 | 0.035 | 0.016 | 0.001 | |
| Price To Book Ratio | 0.732 | 3.835 | -111.497 | -6.540 | -180.444 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -0.297 | -1.895 | -3.339 | -1.358 | -172.477 | |
| Price To Operating Cash Flow Ratio | -0.301 | -1.895 | -3.339 | -1.358 | -172.477 | |
| Debt To Assets Ratio | 0.041 | 0.054 | 0.316 | 0.753 | 1.049 | |
| Debt To Equity Ratio | 0.095 | 0.081 | -2.647 | -1.194 | -2.185 | |
| Debt To Capital Ratio | 0.087 | 0.075 | 1.607 | 6.162 | 1.844 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | -0.039 | -1.292 | |
| Financial Leverage Ratio | 2.319 | 1.509 | -8.388 | -1.584 | -2.084 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.709 | -3.399 | -3.234 | -1.890 | -0.500 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.016 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -31.188 | -4.207 | -8.499 | -5.507 | -1.983 | |
| Interest Coverage Ratio | -545.689 | -5.217 | -30.282 | -221.156 | -15.344 | |
| Short Term Operating Cash Flow Coverage Ratio | -25.452 | -24.871 | -12.613 | -4.192 | -0.647 | |
| Operating Cash Flow Coverage Ratio | -25.452 | -24.871 | -12.613 | -4.034 | -0.479 | |
| Capital Expenditure Coverage Ratio | -63.136 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -63.136 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 0.163 | -1.646 | -3.478 | -1.061 | -51.221 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 1.586 | ▼-0.836 | ▲0.345 |
| Quick Ratio | 1.586 | ▼-0.836 | ▲0.339 |
| Solvency Ratio | -2.226 | ▲1.376 | ▲0.295 |
| Cash Ratio | 0.944 | ▼-0.643 | ▲0.155 |
| Price To Earnings Ratio | -0.231 | ▲1.550 | ▲10.557 |
| Price To Earnings Growth Ratio | 0.018 | ▼-0.678 | ▼-0.135 |
| Forward Price To Earnings Growth Ratio | 0.018 | ▼-0.678 | ▼-0.135 |
| Price To Earnings Diluted Ratio | -0.231 | ▲1.550 | ▲10.557 |
| Price To Earnings Diluted Growth Ratio | 0.018 | ▼-0.678 | ▼-0.135 |
| Price To Book Ratio | 0.732 | ▼-3.103 | ▲59.515 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -0.297 | ▲1.599 | ▲35.577 |
| Price To Operating Cash Flow Ratio | -0.301 | ▲1.594 | ▲35.573 |
| Debt To Assets Ratio | 0.041 | ▼-0.013 | ▼-0.401 |
| Debt To Equity Ratio | 0.095 | ▲0.014 | ▲1.265 |
| Debt To Capital Ratio | 0.087 | ▲0.012 | ▼-1.868 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▲0.266 |
| Financial Leverage Ratio | 2.319 | ▲0.810 | ▲3.965 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -1.709 | ▲1.690 | ▲0.438 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.016 | ▲0.016 | ▲0.013 |
| Debt Service Coverage Ratio | -31.188 | ▼-26.981 | ▼-20.911 |
| Interest Coverage Ratio | -545.689 | ▼-540.472 | ▼-382.151 |
| Short Term Operating Cash Flow Coverage Ratio | -25.452 | ▼-0.581 | ▼-11.897 |
| Operating Cash Flow Coverage Ratio | -25.452 | ▼-0.581 | ▼-11.962 |
| Capital Expenditure Coverage Ratio | -63.136 | ▼-63.136 | ▼-50.509 |
| Dividend Paid And Capex Coverage Ratio | -63.136 | ▼-63.136 | ▼-50.509 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 0.163 | ▲1.808 | ▲11.611 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.4M | $14.2M | $36.0M | $24.3M | $1.42B | |
| Enterprise value | -$1.7M | $11.0M | $35.7M | $25.6M | $1.43B | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | 0.21x | -1.47x | -3.31x | -1.43x | -173.08x | |
| EV / Free cash flow | 0.21x | -1.47x | -3.31x | -1.43x | -173.08x | |
| EV / EBITDA | 0.16x | -1.65x | -3.48x | -1.06x | -51.22x | |
| Net debt / EBITDA | 0.39x | 0.48x | 0.03x | -0.05x | -0.18x | |
| Current ratio | 1.59x | 2.42x | 0.69x | 0.56x | 0.95x | |
| Income quality | 0.77x | 0.94x | 1.01x | 0.74x | 0.28x | |
| Graham net-net | $0 | $1 | -$1 | -$36 | -$145 | |
| Tax burden | 100.0% | 100.0% | 99.9% | 99.9% | 99.8% | |
| Interest burden | 100.2% | 119.3% | 103.4% | 100.5% | 104.7% | |
| Working capital | $2.7M | $3.1M | -$1.0M | -$4.2M | -$819K | |
| Invested capital | $2.8M | $3.1M | -$1.0M | -$4.2M | $24.72B | |
| Return on assets | -136.5% | -142.7% | -391.9% | -410.7% | -177.2% | |
| Operating ROA | -157.0% | -162.1% | -249.5% | -217.2% | -237.0% | |
| Return on tangible assets | -136.5% | -142.7% | -391.9% | -410.7% | -177.2% | |
| Return on equity | -316.6% | -215.4% | 3287.2% | 650.8% | 369.2% | |
| Return on invested capital | -320.9% | -182.3% | -4663.8% | -3388.8% | -156.4% | |
| Return on capital employed | -355.0% | -198.5% | 1715.2% | 676.8% | 30894.5% | |
| Earnings yield | -432.6% | -56.2% | -29.5% | -99.5% | -2.0% | |
| Free cash flow yield | -337.1% | -52.8% | -29.9% | -73.6% | -0.6% | |
| Capex / Op. cash flow | -1.6% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 1892.6% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-18 Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript
- 2026-08-13 Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome Up to $77 million in new funding with the acquisition of Cy Biopharma Company to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today reported financial and operational results for the second quarter ended June 30, 2026.
- 2026-08-13 Ensysce Biosciences (NASDAQ:ENSC) versus CannAmerica Brands (OTCMKTS:CNNXF) Head to Head Review Ensysce Biosciences (NASDAQ: ENSC - Get Free Report) and CannAmerica Brands (OTCMKTS:CNNXF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Valuation and Earnings This table compares Ensysce Biosciences
- 2026-08-06 Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) Up to $77 million in private financing consisting of $21.5 million in private placement financing at initial close plus $17.1 million of Cy Biopharma''s cash and cash equivalents from a pre-acquisition convertible note financing and up to $38.6 million upon achievement of clinical trial milestone Pro forma cash expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") today announced it has completed the acquisition of Cy Biopharma, Inc. ("Cy Biopharma"), a privately held clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain. Concurrent with the acquisition that brought in $17.1 million in cash from a pre-acquisition convertible note financing, Ensysce entered into a definitive agreement for the sale of Series C non-voting convertible preferred stock (with a conversion ratio of preferred to common at 1:1,000) (the "Series C Preferred Stock") in a private placement financing, which is expected to result in gross proceeds to the Company of approximately $21.5 million at the initial close before deducting placement agent fees and other offering and transaction expenses, and includes up to a $38.6 million follow-on tranche that is expected to fund development of CY200 into 2028.
- 2026-07-14 Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced receipt of a Notice of Award for $5.3 million from the National Institutes on Drug Abuse (NIDA)1 to support the development of its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology, and the lead agent, PF614-MPAR. This marks the third consecutive year of NIDA funding under this award, reflecting sustained institutional confidence in the MPAR® program as it progresses toward late-stage development.
- 2026-06-26 Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study ~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced initiation of the final stage of the PF614-MPAR-102 clinical study. The study is evaluating its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology.